NTLANasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends December 31
Intellia Therapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$11.58+0.16 (+1.40%)
Close on Oct 19, 2026
- Market cap
- $1.55B
- P/E (TTM)
- –
- Dividend yield
- –
Share price
−$13.17 (−53.21%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
Intellia Therapeutics, Inc. grew revenue 12.6% to $59.51M over the twelve months to Jun 30, 2026. Free cash flow was -$348.69M.
Revenue
$59.51M
+12.6% vs. a year earlier
Operating income
-$423.48M
TTM Q2 2026
Free cash flow
-$348.69M
TTM Q2 2026
EPS, diluted
-$3.36
TTM Q2 2026
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $1.55B
- P/E ratio
- –
- Price to sales
- 25.98
- Price to book
- 2.12
- Dividend yield
- –
- Free cash flow yield
- -22.56%
Fundamentals
- Revenue
- $59.51M
- Net income
- -$399.98M
- EPS, diluted
- -$3.36
- Free cash flow
- -$348.69M
- Book value per share
- $5.45
- Diluted shares
- 133M
Twelve years at a glance
Fiscal years 2014 to 2025 and trailing twelve months, USD
Revenue
$59.51M+12.6% YoY
Gross profit
–
Operating income
-$423.48M
Net income
-$399.98M
EPS, diluted
-$3.36
Free cash flow
-$348.69M
Reported periodTrailing twelve months